A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy

Blood

Volumn 82, Issue 9, 1993, Pages 2624-2633

  Amlot, P L ^a   Stone, M J ^a   Cunningham, D ^a   Fay, J ^a   Newman, J ^a   Collins, R ^a   May, R ^a   McCarthy, M ^a   Richardson, J ^a   Ghetie, V ^a   Ramilo, O ^a   Thorpe, P E ^a   Uhr, J W ^a   Vitetta, E S ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIBODY; B LYMPHOCYTE ANTIGEN; CD5 ANTIGEN; CORTICOSTEROID; CREATINE KINASE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOTOXIN; LYMPHOCYTE ANTIGEN; RICIN ANTIBODY; T LYMPHOCYTE ANTIGEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; B CELL LYMPHOMA; CLINICAL ARTICLE; DAUDI CELL; DEGLYCOSYLATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; EDEMA; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOALBUMINEMIA; IMMUNOHISTOLOGY; IMMUNOPHENOTYPING; INTRAVENOUS DRUG ADMINISTRATION; LD 50; LUNG EDEMA; MALE; MYALGIA; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SPLENOMEGALY; TOXICITY; WEIGHT GAIN;

EID: 0027374447     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v82.9.2624.bloodjournal8292624     Document Type: Article

References (0)